 Andrea Gaedigk
Concepts (571)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cytochrome P-450 CYP2D6 | 110 | 2023 | 183 | 21.810 |
Why?
| | Pharmacogenetics | 58 | 2023 | 171 | 10.300 |
Why?
| | Cytochrome P-450 Enzyme System | 40 | 2024 | 110 | 7.730 |
Why?
| | Alleles | 60 | 2023 | 213 | 7.330 |
Why?
| | Genotype | 108 | 2024 | 408 | 6.990 |
Why?
| | Humans | 210 | 2024 | 6929 | 5.510 |
Why?
| | Haplotypes | 27 | 2024 | 90 | 5.040 |
Why?
| | Genetic Variation | 30 | 2024 | 166 | 4.780 |
Why?
| | Polymorphism, Genetic | 32 | 2021 | 100 | 4.360 |
Why?
| | Cytochrome P-450 CYP2C19 | 28 | 2024 | 68 | 4.110 |
Why?
| | Genetic Testing | 11 | 2023 | 86 | 3.310 |
Why?
| | Polymorphism, Single Nucleotide | 26 | 2021 | 348 | 3.300 |
Why?
| | Cytochrome P-450 CYP3A | 13 | 2023 | 47 | 3.190 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 21 | 2024 | 58 | 3.180 |
Why?
| | Polymerase Chain Reaction | 24 | 2021 | 85 | 2.770 |
Why?
| | Cytochrome P-450 CYP2C9 | 16 | 2022 | 29 | 2.760 |
Why?
| | Gene Frequency | 32 | 2021 | 91 | 2.750 |
Why?
| | Phenotype | 53 | 2023 | 256 | 2.730 |
Why?
| | DNA Copy Number Variations | 13 | 2023 | 36 | 2.670 |
Why?
| | Dextromethorphan | 30 | 2022 | 55 | 2.430 |
Why?
| | Liver | 19 | 2020 | 130 | 2.280 |
Why?
| | Genotyping Techniques | 9 | 2021 | 21 | 2.090 |
Why?
| | Terminology as Topic | 6 | 2018 | 15 | 2.040 |
Why?
| | High-Throughput Nucleotide Sequencing | 5 | 2022 | 100 | 1.840 |
Why?
| | Cytochrome P-450 CYP2B6 | 6 | 2023 | 10 | 1.800 |
Why?
| | Male | 76 | 2021 | 3367 | 1.770 |
Why?
| | Female | 77 | 2021 | 3534 | 1.730 |
Why?
| | Adult | 53 | 2024 | 1199 | 1.490 |
Why?
| | Databases, Genetic | 3 | 2019 | 27 | 1.440 |
Why?
| | Child | 49 | 2024 | 3348 | 1.350 |
Why?
| | Biotransformation | 16 | 2020 | 49 | 1.340 |
Why?
| | Knowledge Bases | 5 | 2022 | 6 | 1.340 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2022 | 22 | 1.340 |
Why?
| | Antidepressive Agents | 6 | 2023 | 20 | 1.190 |
Why?
| | Gene Duplication | 5 | 2019 | 10 | 1.160 |
Why?
| | Pharmaceutical Preparations | 9 | 2023 | 37 | 1.150 |
Why?
| | Depressive Disorder, Major | 4 | 2023 | 14 | 1.130 |
Why?
| | Glucuronosyltransferase | 6 | 2020 | 16 | 1.120 |
Why?
| | Adolescent | 41 | 2024 | 2183 | 1.100 |
Why?
| | Pyrophosphatases | 3 | 2022 | 4 | 1.090 |
Why?
| | Precision Medicine | 5 | 2021 | 43 | 1.090 |
Why?
| | Aging | 7 | 2021 | 39 | 1.090 |
Why?
| | Consensus | 5 | 2023 | 33 | 1.040 |
Why?
| | Medication Therapy Management | 3 | 2019 | 8 | 1.000 |
Why?
| | Analgesics, Opioid | 9 | 2021 | 43 | 0.980 |
Why?
| | Middle Aged | 33 | 2021 | 645 | 0.980 |
Why?
| | Fluorouracil | 1 | 2024 | 5 | 0.960 |
Why?
| | Gene Dosage | 3 | 2021 | 13 | 0.960 |
Why?
| | Tacrolimus | 2 | 2022 | 10 | 0.950 |
Why?
| | Dihydrouracil Dehydrogenase (NADP) | 1 | 2024 | 5 | 0.940 |
Why?
| | DNA | 10 | 2023 | 44 | 0.930 |
Why?
| | Codeine | 8 | 2021 | 15 | 0.900 |
Why?
| | Proton Pump Inhibitors | 5 | 2024 | 17 | 0.860 |
Why?
| | Inactivation, Metabolic | 4 | 2021 | 15 | 0.860 |
Why?
| | Cytochrome P-450 CYP2C8 | 1 | 2022 | 3 | 0.830 |
Why?
| | Databases, Factual | 2 | 2019 | 108 | 0.820 |
Why?
| | Trichophyton | 3 | 2007 | 5 | 0.820 |
Why?
| | Alternative Splicing | 4 | 2013 | 18 | 0.810 |
Why?
| | RNA, Messenger | 9 | 2017 | 115 | 0.800 |
Why?
| | Child, Preschool | 26 | 2022 | 1562 | 0.770 |
Why?
| | Genetic Association Studies | 3 | 2019 | 54 | 0.760 |
Why?
| | Aged | 18 | 2021 | 411 | 0.750 |
Why?
| | Microsomes, Liver | 10 | 2021 | 45 | 0.740 |
Why?
| | Arylsulfotransferase | 6 | 2011 | 8 | 0.740 |
Why?
| | Molecular Sequence Data | 16 | 2015 | 78 | 0.730 |
Why?
| | Infant | 24 | 2022 | 1449 | 0.730 |
Why?
| | Young Adult | 22 | 2022 | 641 | 0.720 |
Why?
| | Genetics, Population | 3 | 2016 | 11 | 0.690 |
Why?
| | Infant, Newborn | 18 | 2022 | 826 | 0.660 |
Why?
| | Tinea | 3 | 2007 | 4 | 0.650 |
Why?
| | Atomoxetine Hydrochloride | 4 | 2021 | 10 | 0.640 |
Why?
| | Antipsychotic Agents | 4 | 2021 | 14 | 0.640 |
Why?
| | Venlafaxine Hydrochloride | 1 | 2018 | 2 | 0.630 |
Why?
| | Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2018 | 4 | 0.620 |
Why?
| | Omeprazole | 7 | 2010 | 14 | 0.610 |
Why?
| | Models, Biological | 6 | 2021 | 63 | 0.600 |
Why?
| | Hypercholesterolemia | 3 | 2024 | 12 | 0.570 |
Why?
| | DNA Mutational Analysis | 2 | 2014 | 43 | 0.560 |
Why?
| | Sequence Analysis, DNA | 6 | 2018 | 116 | 0.560 |
Why?
| | Bupropion | 1 | 2015 | 3 | 0.540 |
Why?
| | Base Sequence | 13 | 2020 | 87 | 0.530 |
Why?
| | Minor Histocompatibility Antigens | 4 | 2020 | 12 | 0.530 |
Why?
| | Arylamine N-Acetyltransferase | 10 | 2010 | 18 | 0.520 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2013 | 47 | 0.510 |
Why?
| | 2-Pyridinylmethylsulfinylbenzimidazoles | 3 | 2022 | 7 | 0.500 |
Why?
| | Anti-Ulcer Agents | 4 | 2010 | 10 | 0.490 |
Why?
| | MicroRNAs | 4 | 2017 | 26 | 0.490 |
Why?
| | Mixed Function Oxygenases | 9 | 2006 | 25 | 0.490 |
Why?
| | Exons | 9 | 2013 | 35 | 0.490 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 4 | 2020 | 18 | 0.480 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 3 | 2020 | 39 | 0.480 |
Why?
| | Anticonvulsants | 7 | 2020 | 27 | 0.470 |
Why?
| | Computational Biology | 5 | 2020 | 42 | 0.460 |
Why?
| | Genetic Loci | 5 | 2019 | 40 | 0.450 |
Why?
| | Antimalarials | 2 | 2023 | 7 | 0.440 |
Why?
| | Age Factors | 10 | 2020 | 211 | 0.440 |
Why?
| | Gene Expression Regulation, Enzymologic | 6 | 2015 | 20 | 0.440 |
Why?
| | Oxygenases | 2 | 2017 | 5 | 0.430 |
Why?
| | Acetaminophen | 4 | 2019 | 18 | 0.430 |
Why?
| | Brain | 3 | 2011 | 79 | 0.420 |
Why?
| | Promoter Regions, Genetic | 4 | 2018 | 50 | 0.410 |
Why?
| | Phenytoin | 3 | 2020 | 8 | 0.410 |
Why?
| | Population | 1 | 2011 | 2 | 0.410 |
Why?
| | Clinical Decision-Making | 3 | 2020 | 19 | 0.400 |
Why?
| | Sulfotransferases | 4 | 2019 | 7 | 0.390 |
Why?
| | Substrate Specificity | 9 | 2016 | 18 | 0.380 |
Why?
| | DNA Primers | 8 | 2015 | 30 | 0.370 |
Why?
| | Models, Genetic | 2 | 2007 | 33 | 0.370 |
Why?
| | Reference Standards | 2 | 2021 | 15 | 0.370 |
Why?
| | Mycological Typing Techniques | 2 | 2007 | 3 | 0.370 |
Why?
| | Multiplex Polymerase Chain Reaction | 2 | 2021 | 9 | 0.370 |
Why?
| | Ondansetron | 2 | 2022 | 3 | 0.370 |
Why?
| | Microfluidic Analytical Techniques | 1 | 2010 | 3 | 0.370 |
Why?
| | Warfarin | 7 | 2018 | 16 | 0.360 |
Why?
| | Disulfides | 1 | 2010 | 2 | 0.360 |
Why?
| | Tandem Repeat Sequences | 1 | 2010 | 4 | 0.360 |
Why?
| | Indians, North American | 3 | 2013 | 9 | 0.360 |
Why?
| | DNA, Fungal | 2 | 2007 | 6 | 0.360 |
Why?
| | Dose-Response Relationship, Drug | 12 | 2020 | 96 | 0.360 |
Why?
| | Xanthine Oxidase | 8 | 2010 | 14 | 0.350 |
Why?
| | Debrisoquin | 4 | 2002 | 5 | 0.340 |
Why?
| | Central Nervous System Stimulants | 4 | 2016 | 11 | 0.340 |
Why?
| | NAD(P)H Dehydrogenase (Quinone) | 2 | 2000 | 5 | 0.340 |
Why?
| | Algorithms | 2 | 2019 | 108 | 0.330 |
Why?
| | Drug Dosage Calculations | 4 | 2018 | 16 | 0.330 |
Why?
| | Benzoxazines | 2 | 2019 | 2 | 0.330 |
Why?
| | Immunosuppressive Agents | 2 | 2022 | 32 | 0.320 |
Why?
| | Breast Feeding | 4 | 2011 | 24 | 0.320 |
Why?
| | Anticoagulants | 4 | 2018 | 20 | 0.310 |
Why?
| | Cytochrome P-450 CYP2D6 Inhibitors | 4 | 2020 | 11 | 0.310 |
Why?
| | Epoxide Hydrolases | 3 | 1997 | 6 | 0.310 |
Why?
| | Adrenergic Uptake Inhibitors | 2 | 2019 | 6 | 0.310 |
Why?
| | Aged, 80 and over | 8 | 2018 | 168 | 0.300 |
Why?
| | Fetus | 2 | 2011 | 19 | 0.300 |
Why?
| | Metabolomics | 2 | 2020 | 16 | 0.300 |
Why?
| | Healthy Volunteers | 4 | 2021 | 8 | 0.300 |
Why?
| | Fungal Proteins | 1 | 2007 | 10 | 0.300 |
Why?
| | Isoenzymes | 8 | 2017 | 23 | 0.290 |
Why?
| | Genetic Heterogeneity | 1 | 2007 | 5 | 0.290 |
Why?
| | Area Under Curve | 10 | 2019 | 34 | 0.290 |
Why?
| | Dextrorphan | 8 | 2022 | 13 | 0.290 |
Why?
| | Steroid 16-alpha-Hydroxylase | 3 | 2001 | 8 | 0.290 |
Why?
| | Steroid Hydroxylases | 3 | 2001 | 13 | 0.290 |
Why?
| | Breath Tests | 2 | 2022 | 11 | 0.290 |
Why?
| | Thailand | 3 | 2021 | 3 | 0.290 |
Why?
| | Bipolar Disorder | 2 | 2016 | 4 | 0.280 |
Why?
| | Ethanolamines | 2 | 2005 | 4 | 0.270 |
Why?
| | Pathology, Molecular | 2 | 2023 | 3 | 0.270 |
Why?
| | Gene Rearrangement | 1 | 2006 | 7 | 0.270 |
Why?
| | Baclofen | 2 | 2017 | 9 | 0.270 |
Why?
| | Trinidad and Tobago | 2 | 2018 | 2 | 0.270 |
Why?
| | Methyltransferases | 2 | 2022 | 9 | 0.270 |
Why?
| | HIV Infections | 3 | 2019 | 52 | 0.260 |
Why?
| | Gene Expression Regulation | 2 | 2019 | 103 | 0.260 |
Why?
| | Morphine | 5 | 2021 | 11 | 0.260 |
Why?
| | Gene Expression Regulation, Developmental | 3 | 2015 | 50 | 0.260 |
Why?
| | Cerebral Palsy | 2 | 2017 | 18 | 0.260 |
Why?
| | Polymorphism, Restriction Fragment Length | 7 | 2013 | 11 | 0.260 |
Why?
| | Reproducibility of Results | 4 | 2019 | 198 | 0.260 |
Why?
| | Antidepressive Agents, Tricyclic | 2 | 2017 | 5 | 0.260 |
Why?
| | Prevalence | 2 | 2021 | 150 | 0.260 |
Why?
| | Body Weight | 3 | 2018 | 52 | 0.250 |
Why?
| | Prospective Studies | 7 | 2022 | 547 | 0.240 |
Why?
| | Antitussive Agents | 5 | 2010 | 13 | 0.240 |
Why?
| | Cytochrome P-450 CYP1A2 | 6 | 2008 | 12 | 0.240 |
Why?
| | Capecitabine | 1 | 2024 | 1 | 0.240 |
Why?
| | Transcription, Genetic | 4 | 2013 | 45 | 0.240 |
Why?
| | RNA, Fungal | 1 | 2003 | 1 | 0.240 |
Why?
| | DNA, Ribosomal | 1 | 2003 | 3 | 0.240 |
Why?
| | RNA, Ribosomal | 1 | 2003 | 3 | 0.240 |
Why?
| | Rosuvastatin Calcium | 2 | 2022 | 5 | 0.230 |
Why?
| | Testosterone | 3 | 2020 | 31 | 0.230 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2024 | 24 | 0.230 |
Why?
| | Citalopram | 2 | 2023 | 14 | 0.230 |
Why?
| | Genome-Wide Association Study | 3 | 2023 | 184 | 0.230 |
Why?
| | Netherlands | 2 | 2021 | 5 | 0.230 |
Why?
| | Indomethacin | 1 | 2022 | 4 | 0.220 |
Why?
| | Binding Sites | 4 | 2017 | 27 | 0.220 |
Why?
| | Tonsillectomy | 1 | 2022 | 11 | 0.220 |
Why?
| | Hydroxylation | 6 | 2016 | 14 | 0.220 |
Why?
| | Biomarkers | 5 | 2020 | 132 | 0.220 |
Why?
| | Cohort Studies | 6 | 2017 | 281 | 0.220 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2022 | 1 | 0.210 |
Why?
| | Propafenone | 1 | 2022 | 1 | 0.210 |
Why?
| | Long QT Syndrome | 1 | 2022 | 3 | 0.210 |
Why?
| | Drug Prescriptions | 2 | 2020 | 20 | 0.210 |
Why?
| | Cyclosporine | 1 | 2022 | 6 | 0.210 |
Why?
| | Simvastatin | 2 | 2022 | 10 | 0.210 |
Why?
| | Prodrugs | 1 | 2022 | 2 | 0.210 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2022 | 6 | 0.210 |
Why?
| | Genetics, Medical | 1 | 2022 | 5 | 0.210 |
Why?
| | Cytosol | 2 | 2019 | 14 | 0.210 |
Why?
| | Antidepressive Agents, Second-Generation | 2 | 2016 | 4 | 0.210 |
Why?
| | Pain | 2 | 2021 | 56 | 0.200 |
Why?
| | Computer Simulation | 3 | 2020 | 31 | 0.200 |
Why?
| | Infant, Premature | 1 | 2022 | 86 | 0.200 |
Why?
| | Gene Deletion | 2 | 2011 | 14 | 0.200 |
Why?
| | Postoperative Nausea and Vomiting | 2 | 2022 | 6 | 0.200 |
Why?
| | Chromosome Mapping | 2 | 2003 | 35 | 0.200 |
Why?
| | Gastroesophageal Reflux | 2 | 2020 | 41 | 0.200 |
Why?
| | Proteins | 1 | 2021 | 27 | 0.200 |
Why?
| | Cluster Analysis | 3 | 2015 | 43 | 0.200 |
Why?
| | Pharmacokinetics | 1 | 2021 | 14 | 0.200 |
Why?
| | Animals | 10 | 2010 | 741 | 0.200 |
Why?
| | Carboxy-Lyases | 1 | 2021 | 1 | 0.200 |
Why?
| | Vitamin K Epoxide Reductases | 1 | 2021 | 4 | 0.200 |
Why?
| | Egypt | 1 | 2021 | 1 | 0.200 |
Why?
| | Arabs | 1 | 2021 | 2 | 0.200 |
Why?
| | Drug Interactions | 7 | 2020 | 32 | 0.200 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2019 | 41 | 0.200 |
Why?
| | Spain | 2 | 2011 | 3 | 0.190 |
Why?
| | Risperidone | 1 | 2021 | 2 | 0.190 |
Why?
| | Catechol O-Methyltransferase | 1 | 2021 | 5 | 0.190 |
Why?
| | Receptors, Opioid, mu | 1 | 2021 | 4 | 0.190 |
Why?
| | Carbamazepine | 2 | 1998 | 10 | 0.190 |
Why?
| | Milk, Human | 3 | 2011 | 24 | 0.190 |
Why?
| | Psychiatry | 1 | 2020 | 1 | 0.190 |
Why?
| | Genes | 3 | 2015 | 10 | 0.190 |
Why?
| | United States | 4 | 2022 | 670 | 0.190 |
Why?
| | HLA-B Antigens | 1 | 2020 | 7 | 0.190 |
Why?
| | Sertraline | 2 | 2019 | 11 | 0.190 |
Why?
| | Pimozide | 1 | 2020 | 4 | 0.190 |
Why?
| | Polymorphism, Single-Stranded Conformational | 2 | 2019 | 4 | 0.190 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 7 | 0.180 |
Why?
| | Caffeine | 5 | 2010 | 13 | 0.180 |
Why?
| | Cloning, Molecular | 4 | 2005 | 11 | 0.180 |
Why?
| | 3' Untranslated Regions | 2 | 2017 | 10 | 0.180 |
Why?
| | Marketing of Health Services | 1 | 2019 | 3 | 0.180 |
Why?
| | Drug Labeling | 1 | 2019 | 4 | 0.180 |
Why?
| | Breast Neoplasms | 2 | 2018 | 39 | 0.180 |
Why?
| | Delphi Technique | 1 | 2019 | 11 | 0.180 |
Why?
| | Phenylethyl Alcohol | 1 | 2019 | 1 | 0.180 |
Why?
| | Wine | 1 | 2019 | 1 | 0.180 |
Why?
| | Schizophrenia | 2 | 2010 | 3 | 0.180 |
Why?
| | Cardiovascular System | 1 | 2019 | 4 | 0.180 |
Why?
| | Cytochrome P-450 CYP2A6 | 1 | 2019 | 3 | 0.170 |
Why?
| | Drug Resistance | 1 | 2019 | 7 | 0.170 |
Why?
| | Sequence Alignment | 2 | 2015 | 11 | 0.170 |
Why?
| | HIV-1 | 1 | 2019 | 26 | 0.170 |
Why?
| | Administration, Oral | 8 | 2017 | 58 | 0.170 |
Why?
| | Pravastatin | 1 | 2019 | 7 | 0.170 |
Why?
| | Treatment Outcome | 5 | 2023 | 649 | 0.170 |
Why?
| | Mutation, Missense | 1 | 2018 | 28 | 0.160 |
Why?
| | Glucuronides | 1 | 2018 | 3 | 0.160 |
Why?
| | Predictive Value of Tests | 4 | 2020 | 102 | 0.160 |
Why?
| | Proteomics | 4 | 2021 | 22 | 0.160 |
Why?
| | Drug Hypersensitivity | 3 | 1996 | 19 | 0.160 |
Why?
| | Growth Disorders | 2 | 2008 | 25 | 0.160 |
Why?
| | Autoantigens | 1 | 1998 | 5 | 0.160 |
Why?
| | Population Surveillance | 1 | 2018 | 13 | 0.160 |
Why?
| | Pharmacists | 3 | 2023 | 4 | 0.160 |
Why?
| | Androgens | 1 | 2018 | 8 | 0.160 |
Why?
| | Software | 1 | 2018 | 26 | 0.160 |
Why?
| | Tamoxifen | 1 | 2018 | 1 | 0.160 |
Why?
| | Indians, South American | 1 | 2018 | 1 | 0.160 |
Why?
| | Muscle Relaxants, Central | 2 | 2017 | 7 | 0.160 |
Why?
| | Recombinant Proteins | 5 | 2020 | 52 | 0.160 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 275 | 0.160 |
Why?
| | Kinetics | 6 | 2008 | 34 | 0.160 |
Why?
| | Cytochrome P-450 CYP2B6 Inducers | 1 | 2017 | 1 | 0.150 |
Why?
| | Opioid-Related Disorders | 2 | 2008 | 14 | 0.150 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2017 | 3 | 0.150 |
Why?
| | Alcohol Dehydrogenase | 1 | 2017 | 4 | 0.150 |
Why?
| | Metabolic Clearance Rate | 4 | 2014 | 18 | 0.150 |
Why?
| | Hypersensitivity | 1 | 1998 | 56 | 0.150 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2005 | 72 | 0.150 |
Why?
| | Diabetic Neuropathies | 1 | 2017 | 1 | 0.150 |
Why?
| | Pilot Projects | 5 | 2022 | 114 | 0.150 |
Why?
| | Amitriptyline | 1 | 2017 | 4 | 0.150 |
Why?
| | Chromosomes, Human, Pair 16 | 1 | 1997 | 2 | 0.150 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2016 | 2 | 0.140 |
Why?
| | Carboxylesterase | 1 | 2016 | 2 | 0.140 |
Why?
| | Oseltamivir | 1 | 2016 | 6 | 0.140 |
Why?
| | Sparteine | 4 | 1998 | 4 | 0.140 |
Why?
| | Depression | 3 | 2023 | 68 | 0.140 |
Why?
| | Mutation | 5 | 2010 | 213 | 0.140 |
Why?
| | Organic Anion Transporters, Sodium-Independent | 1 | 2016 | 3 | 0.140 |
Why?
| | Multidrug Resistance-Associated Proteins | 1 | 2016 | 5 | 0.140 |
Why?
| | Organic Cation Transporter 1 | 1 | 2016 | 4 | 0.140 |
Why?
| | Hepatocytes | 2 | 2013 | 8 | 0.140 |
Why?
| | Fluoxetine | 2 | 2014 | 5 | 0.140 |
Why?
| | South Africa | 3 | 2015 | 7 | 0.140 |
Why?
| | Pediatric Obesity | 1 | 2018 | 130 | 0.130 |
Why?
| | Risk Assessment | 4 | 2020 | 136 | 0.130 |
Why?
| | RNA Splicing | 2 | 2006 | 12 | 0.130 |
Why?
| | Sulfates | 3 | 2019 | 6 | 0.130 |
Why?
| | Case-Control Studies | 5 | 2019 | 216 | 0.130 |
Why?
| | Gestational Age | 1 | 2015 | 64 | 0.130 |
Why?
| | Genomics | 2 | 2022 | 102 | 0.130 |
Why?
| | Sex Factors | 5 | 2020 | 68 | 0.130 |
Why?
| | Practice Guidelines as Topic | 3 | 2020 | 104 | 0.130 |
Why?
| | Enzyme Activation | 2 | 2018 | 12 | 0.120 |
Why?
| | False Negative Reactions | 1 | 2014 | 10 | 0.120 |
Why?
| | Research | 1 | 2014 | 12 | 0.120 |
Why?
| | Pregnancy | 3 | 2021 | 212 | 0.120 |
Why?
| | Mental Disorders | 2 | 2013 | 16 | 0.120 |
Why?
| | RNA | 3 | 2005 | 14 | 0.120 |
Why?
| | Obsessive-Compulsive Disorder | 2 | 2020 | 6 | 0.120 |
Why?
| | Risk Factors | 4 | 2020 | 490 | 0.120 |
Why?
| | COS Cells | 3 | 2002 | 19 | 0.120 |
Why?
| | Puerto Rico | 2 | 2010 | 3 | 0.120 |
Why?
| | Tramadol | 2 | 2005 | 4 | 0.120 |
Why?
| | Rifampin | 1 | 2013 | 7 | 0.120 |
Why?
| | Amphetamine-Related Disorders | 1 | 2013 | 1 | 0.110 |
Why?
| | Methamphetamine | 1 | 2013 | 2 | 0.110 |
Why?
| | Transition Temperature | 1 | 2013 | 2 | 0.110 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2013 | 9 | 0.110 |
Why?
| | Kidney Transplantation | 1 | 2014 | 115 | 0.110 |
Why?
| | Heart Failure | 1 | 2013 | 14 | 0.110 |
Why?
| | India | 1 | 2013 | 2 | 0.110 |
Why?
| | Tandem Mass Spectrometry | 3 | 2019 | 20 | 0.110 |
Why?
| | Cross-Over Studies | 6 | 2019 | 35 | 0.110 |
Why?
| | Menstrual Cycle | 3 | 2004 | 6 | 0.110 |
Why?
| | Chromatography, High Pressure Liquid | 4 | 2019 | 41 | 0.110 |
Why?
| | Primaquine | 2 | 2023 | 2 | 0.110 |
Why?
| | Metoprolol | 2 | 2019 | 3 | 0.110 |
Why?
| | Oxidoreductases, N-Demethylating | 3 | 2003 | 8 | 0.110 |
Why?
| | Flushing | 1 | 2012 | 4 | 0.110 |
Why?
| | Exanthema | 1 | 2012 | 4 | 0.110 |
Why?
| | Pruritus | 1 | 2012 | 4 | 0.110 |
Why?
| | Erythema | 1 | 2012 | 6 | 0.100 |
Why?
| | Longitudinal Studies | 3 | 2022 | 119 | 0.100 |
Why?
| | Clinical Trials as Topic | 2 | 2010 | 44 | 0.100 |
Why?
| | Vancomycin | 1 | 2012 | 17 | 0.100 |
Why?
| | Hepatocyte Nuclear Factor 4 | 1 | 2012 | 4 | 0.100 |
Why?
| | Saliva | 1 | 2011 | 10 | 0.100 |
Why?
| | Blood | 1 | 2011 | 10 | 0.100 |
Why?
| | Parkinson Disease | 1 | 2011 | 1 | 0.100 |
Why?
| | Midazolam | 4 | 2010 | 12 | 0.100 |
Why?
| | Chromosomes, Human, Pair 22 | 1 | 1991 | 6 | 0.100 |
Why?
| | Genetic Markers | 2 | 2016 | 22 | 0.100 |
Why?
| | Introns | 2 | 2005 | 9 | 0.100 |
Why?
| | Chromosome Deletion | 1 | 1991 | 21 | 0.100 |
Why?
| | Restriction Mapping | 3 | 1997 | 7 | 0.090 |
Why?
| | Hep G2 Cells | 3 | 2017 | 6 | 0.090 |
Why?
| | Retrospective Studies | 3 | 2022 | 1337 | 0.090 |
Why?
| | China | 2 | 2001 | 10 | 0.090 |
Why?
| | Canada | 2 | 2001 | 34 | 0.090 |
Why?
| | Hybridization, Genetic | 1 | 2010 | 3 | 0.090 |
Why?
| | Luciferases | 2 | 2012 | 6 | 0.090 |
Why?
| | Genes, Reporter | 2 | 2012 | 13 | 0.090 |
Why?
| | HLA Antigens | 2 | 2020 | 13 | 0.090 |
Why?
| | Genome, Human | 1 | 2010 | 84 | 0.090 |
Why?
| | Neoplasm Proteins | 2 | 2022 | 31 | 0.090 |
Why?
| | In Vitro Techniques | 3 | 2017 | 25 | 0.090 |
Why?
| | Gene Expression | 2 | 2010 | 67 | 0.080 |
Why?
| | Paroxetine | 2 | 2006 | 3 | 0.080 |
Why?
| | Growth Hormone | 1 | 2008 | 6 | 0.080 |
Why?
| | Alkynes | 2 | 2019 | 2 | 0.080 |
Why?
| | Cyclopropanes | 2 | 2019 | 7 | 0.080 |
Why?
| | Carbon Dioxide | 1 | 2008 | 16 | 0.080 |
Why?
| | Human Growth Hormone | 1 | 2008 | 15 | 0.080 |
Why?
| | Cells, Cultured | 2 | 2013 | 84 | 0.080 |
Why?
| | Abnormalities, Drug-Induced | 1 | 2008 | 8 | 0.080 |
Why?
| | Transfection | 2 | 2012 | 23 | 0.080 |
Why?
| | Linear Models | 1 | 2007 | 57 | 0.080 |
Why?
| | Heterozygote | 3 | 2024 | 27 | 0.070 |
Why?
| | Species Specificity | 1 | 2007 | 10 | 0.070 |
Why?
| | Scalp | 1 | 2007 | 2 | 0.070 |
Why?
| | Epitopes | 2 | 1998 | 20 | 0.070 |
Why?
| | Artifacts | 1 | 2007 | 7 | 0.070 |
Why?
| | Gene Amplification | 1 | 2007 | 4 | 0.070 |
Why?
| | Child Day Care Centers | 1 | 2006 | 1 | 0.070 |
Why?
| | Half-Life | 4 | 2014 | 12 | 0.070 |
Why?
| | Acetyltransferases | 2 | 2003 | 4 | 0.070 |
Why?
| | Urban Population | 1 | 2006 | 27 | 0.070 |
Why?
| | Rats | 3 | 2010 | 112 | 0.070 |
Why?
| | Amino Acid Sequence | 4 | 1999 | 36 | 0.070 |
Why?
| | Fatty Acids, Monounsaturated | 1 | 2006 | 1 | 0.070 |
Why?
| | Indoles | 1 | 2006 | 4 | 0.070 |
Why?
| | Benzimidazoles | 1 | 2006 | 1 | 0.070 |
Why?
| | Ribonucleosides | 1 | 2006 | 1 | 0.070 |
Why?
| | Smoking | 1 | 2006 | 22 | 0.070 |
Why?
| | Open Reading Frames | 1 | 2006 | 3 | 0.070 |
Why?
| | Antiviral Agents | 1 | 2006 | 26 | 0.070 |
Why?
| | Ethinyl Estradiol | 1 | 2005 | 2 | 0.070 |
Why?
| | Norgestrel | 1 | 2005 | 2 | 0.070 |
Why?
| | Contraceptives, Oral | 1 | 2005 | 3 | 0.070 |
Why?
| | Mexican Americans | 1 | 2005 | 2 | 0.070 |
Why?
| | Vitamin K | 2 | 2005 | 5 | 0.070 |
Why?
| | Feasibility Studies | 2 | 2020 | 59 | 0.070 |
Why?
| | Patient Safety | 2 | 2016 | 20 | 0.070 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 333 | 0.060 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2004 | 5 | 0.060 |
Why?
| | Pyrimidinones | 1 | 2004 | 1 | 0.060 |
Why?
| | Ritonavir | 1 | 2004 | 1 | 0.060 |
Why?
| | HIV Protease Inhibitors | 1 | 2004 | 2 | 0.060 |
Why?
| | Mice | 4 | 2010 | 339 | 0.060 |
Why?
| | Blood Specimen Collection | 1 | 2004 | 5 | 0.060 |
Why?
| | Hypertension | 1 | 2004 | 65 | 0.060 |
Why?
| | Genes, Fungal | 1 | 2003 | 1 | 0.060 |
Why?
| | Genome, Fungal | 1 | 2003 | 1 | 0.060 |
Why?
| | DNA, Intergenic | 1 | 2003 | 1 | 0.060 |
Why?
| | Drosophila Proteins | 1 | 2003 | 8 | 0.060 |
Why?
| | Cystic Fibrosis | 1 | 2004 | 20 | 0.060 |
Why?
| | Chloroquine | 1 | 2023 | 1 | 0.060 |
Why?
| | Amino Acid Transport Systems | 1 | 2003 | 1 | 0.060 |
Why?
| | Membrane Proteins | 1 | 2003 | 53 | 0.060 |
Why?
| | Nuclear Proteins | 1 | 2003 | 52 | 0.060 |
Why?
| | Serotonin | 1 | 2023 | 4 | 0.060 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2023 | 7 | 0.060 |
Why?
| | Carrier Proteins | 1 | 2003 | 35 | 0.060 |
Why?
| | Stereoisomerism | 4 | 2006 | 11 | 0.060 |
Why?
| | Forecasting | 1 | 2022 | 24 | 0.050 |
Why?
| | Multigene Family | 2 | 2019 | 7 | 0.050 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2002 | 4 | 0.050 |
Why?
| | Africa | 1 | 2022 | 4 | 0.050 |
Why?
| | Asia | 1 | 2022 | 10 | 0.050 |
Why?
| | Ticlopidine | 1 | 2022 | 2 | 0.050 |
Why?
| | NADPH-Ferrihemoprotein Reductase | 1 | 2021 | 3 | 0.050 |
Why?
| | Mutagenesis, Site-Directed | 2 | 1999 | 23 | 0.050 |
Why?
| | Antifibrinolytic Agents | 1 | 2001 | 3 | 0.050 |
Why?
| | Recombinant Fusion Proteins | 2 | 1999 | 14 | 0.050 |
Why?
| | Paliperidone Palmitate | 1 | 2021 | 2 | 0.050 |
Why?
| | Sensitivity and Specificity | 3 | 2008 | 151 | 0.050 |
Why?
| | Societies, Medical | 1 | 2021 | 50 | 0.050 |
Why?
| | Supervised Machine Learning | 1 | 2020 | 2 | 0.050 |
Why?
| | Urea Cycle Disorders, Inborn | 1 | 2020 | 2 | 0.050 |
Why?
| | Prescription Drugs | 1 | 2020 | 4 | 0.050 |
Why?
| | Academic Medical Centers | 1 | 2020 | 10 | 0.050 |
Why?
| | Esophagitis | 1 | 2020 | 7 | 0.050 |
Why?
| | Gastritis | 1 | 2020 | 12 | 0.050 |
Why?
| | Tourette Syndrome | 1 | 2020 | 6 | 0.050 |
Why?
| | Amines | 2 | 1997 | 4 | 0.050 |
Why?
| | Stevens-Johnson Syndrome | 1 | 2020 | 14 | 0.050 |
Why?
| | Methylation | 2 | 2016 | 11 | 0.050 |
Why?
| | Catecholamines | 1 | 1999 | 7 | 0.040 |
Why?
| | Sequence Deletion | 1 | 2019 | 12 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2019 | 15 | 0.040 |
Why?
| | Drug Combinations | 3 | 2005 | 20 | 0.040 |
Why?
| | Gas Chromatography-Mass Spectrometry | 2 | 2013 | 2 | 0.040 |
Why?
| | Anti-HIV Agents | 1 | 2019 | 10 | 0.040 |
Why?
| | Acetylation | 3 | 2007 | 3 | 0.040 |
Why?
| | Genetic Predisposition to Disease | 2 | 2013 | 226 | 0.040 |
Why?
| | Hospitals, Pediatric | 1 | 2020 | 186 | 0.040 |
Why?
| | Excitatory Amino Acid Antagonists | 3 | 2005 | 6 | 0.040 |
Why?
| | Zidovudine | 1 | 2018 | 2 | 0.040 |
Why?
| | Antimetabolites | 1 | 2018 | 4 | 0.040 |
Why?
| | Homozygote | 3 | 1998 | 22 | 0.040 |
Why?
| | Thromboxane-A Synthase | 1 | 1998 | 2 | 0.040 |
Why?
| | Intramolecular Oxidoreductases | 1 | 1998 | 2 | 0.040 |
Why?
| | Epitope Mapping | 1 | 1998 | 7 | 0.040 |
Why?
| | Fathers | 1 | 2018 | 7 | 0.040 |
Why?
| | Internet | 1 | 2018 | 17 | 0.040 |
Why?
| | Hyperlipidemias | 1 | 2018 | 6 | 0.040 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2018 | 3 | 0.040 |
Why?
| | Mothers | 1 | 2018 | 33 | 0.040 |
Why?
| | Microsomes | 2 | 1995 | 5 | 0.040 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2018 | 33 | 0.040 |
Why?
| | Escherichia coli | 1 | 1998 | 29 | 0.040 |
Why?
| | Sulfonylurea Receptors | 1 | 2017 | 3 | 0.040 |
Why?
| | Sex Characteristics | 1 | 2017 | 12 | 0.040 |
Why?
| | Follow-Up Studies | 1 | 2018 | 329 | 0.040 |
Why?
| | Double-Blind Method | 2 | 2008 | 45 | 0.040 |
Why?
| | Carcinogens | 1 | 1997 | 2 | 0.040 |
Why?
| | Xenobiotics | 1 | 1997 | 3 | 0.040 |
Why?
| | Heterocyclic Compounds | 1 | 1997 | 3 | 0.040 |
Why?
| | Serotonin 5-HT3 Receptor Agonists | 1 | 2017 | 1 | 0.040 |
Why?
| | Random Allocation | 1 | 2017 | 6 | 0.040 |
Why?
| | Radiotherapy | 1 | 2017 | 5 | 0.040 |
Why?
| | Antiemetics | 1 | 2017 | 4 | 0.040 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 1997 | 4 | 0.040 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2017 | 8 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2016 | 10 | 0.040 |
Why?
| | Prognosis | 1 | 2017 | 216 | 0.040 |
Why?
| | Propylamines | 1 | 2016 | 4 | 0.030 |
Why?
| | Phenols | 1 | 2016 | 7 | 0.030 |
Why?
| | Therapeutic Equivalency | 2 | 2006 | 5 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2016 | 12 | 0.030 |
Why?
| | Reference Values | 2 | 2008 | 43 | 0.030 |
Why?
| | Research Design | 1 | 2016 | 63 | 0.030 |
Why?
| | Quality Improvement | 1 | 2016 | 60 | 0.030 |
Why?
| | Mice, Knockout | 2 | 2007 | 60 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2015 | 125 | 0.030 |
Why?
| | Clotrimazole | 1 | 2014 | 3 | 0.030 |
Why?
| | DNA, Complementary | 1 | 1994 | 9 | 0.030 |
Why?
| | Point Mutation | 1 | 1994 | 7 | 0.030 |
Why?
| | Anti-Infective Agents, Local | 1 | 2014 | 8 | 0.030 |
Why?
| | Pedigree | 2 | 2011 | 61 | 0.030 |
Why?
| | Absorption | 1 | 2014 | 7 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2014 | 36 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2014 | 73 | 0.030 |
Why?
| | Models, Statistical | 1 | 2014 | 29 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2014 | 37 | 0.030 |
Why?
| | Northwestern United States | 1 | 2013 | 1 | 0.030 |
Why?
| | Linkage Disequilibrium | 1 | 2013 | 34 | 0.030 |
Why?
| | Substance Abuse Detection | 1 | 2013 | 1 | 0.030 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2013 | 6 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2013 | 35 | 0.030 |
Why?
| | Odds Ratio | 1 | 2013 | 51 | 0.030 |
Why?
| | Enzyme Inhibitors | 2 | 2006 | 22 | 0.030 |
Why?
| | Logistic Models | 1 | 2013 | 85 | 0.030 |
Why?
| | Aminosalicylic Acid | 2 | 2007 | 2 | 0.030 |
Why?
| | Amine Oxidase (Copper-Containing) | 1 | 2012 | 6 | 0.030 |
Why?
| | Syndrome | 1 | 2012 | 34 | 0.030 |
Why?
| | Catalysis | 2 | 2005 | 4 | 0.030 |
Why?
| | Histamine | 1 | 2012 | 13 | 0.030 |
Why?
| | HeLa Cells | 1 | 2012 | 17 | 0.030 |
Why?
| | Plasmids | 1 | 2012 | 7 | 0.030 |
Why?
| | Postmortem Changes | 1 | 2011 | 1 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 1991 | 12 | 0.020 |
Why?
| | Immunohistochemistry | 2 | 2005 | 47 | 0.020 |
Why?
| | Follicular Phase | 2 | 2002 | 3 | 0.020 |
Why?
| | Luteal Phase | 2 | 2002 | 3 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2010 | 21 | 0.020 |
Why?
| | Systems Biology | 1 | 2010 | 4 | 0.020 |
Why?
| | Hospitalization | 1 | 2012 | 209 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2010 | 10 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2010 | 15 | 0.020 |
Why?
| | Catalytic Domain | 2 | 1999 | 4 | 0.020 |
Why?
| | In Situ Hybridization | 2 | 2000 | 11 | 0.020 |
Why?
| | Tissue Distribution | 2 | 2000 | 11 | 0.020 |
Why?
| | Dwarfism, Pituitary | 1 | 2008 | 1 | 0.020 |
Why?
| | Carbon Isotopes | 1 | 2008 | 4 | 0.020 |
Why?
| | Probability | 1 | 2008 | 15 | 0.020 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2008 | 8 | 0.020 |
Why?
| | Apnea | 1 | 2008 | 5 | 0.020 |
Why?
| | Dopamine | 2 | 1999 | 6 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2008 | 27 | 0.020 |
Why?
| | Sequence Homology, Amino Acid | 2 | 1999 | 7 | 0.020 |
Why?
| | Aminobiphenyl Compounds | 1 | 2007 | 1 | 0.020 |
Why?
| | Fluorenes | 1 | 2007 | 1 | 0.020 |
Why?
| | Sulfamethazine | 1 | 2007 | 1 | 0.020 |
Why?
| | Dealkylation | 1 | 2007 | 2 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2007 | 6 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2007 | 90 | 0.020 |
Why?
| | Psychometrics | 1 | 2006 | 30 | 0.020 |
Why?
| | Dehydroepiandrosterone | 1 | 2005 | 2 | 0.020 |
Why?
| | Time Factors | 1 | 2006 | 263 | 0.020 |
Why?
| | Lopinavir | 1 | 2004 | 1 | 0.020 |
Why?
| | Blood Pressure | 1 | 2004 | 65 | 0.020 |
Why?
| | Seizures | 1 | 2004 | 24 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2004 | 14 | 0.010 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2003 | 4 | 0.010 |
Why?
| | Vitamins | 1 | 2003 | 11 | 0.010 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2003 | 2 | 0.010 |
Why?
| | Biological Availability | 1 | 2003 | 8 | 0.010 |
Why?
| | Amino Acid Transport System A | 1 | 2003 | 1 | 0.010 |
Why?
| | Fluvoxamine | 1 | 2002 | 2 | 0.010 |
Why?
| | Least-Squares Analysis | 1 | 2002 | 2 | 0.010 |
Why?
| | International Normalized Ratio | 1 | 2001 | 5 | 0.010 |
Why?
| | Anti-Anxiety Agents | 1 | 2000 | 5 | 0.010 |
Why?
| | Hypnotics and Sedatives | 1 | 2000 | 6 | 0.010 |
Why?
| | RNA Probes | 1 | 2000 | 1 | 0.010 |
Why?
| | Histocytochemistry | 1 | 2000 | 4 | 0.010 |
Why?
| | Crystallization | 1 | 1999 | 1 | 0.010 |
Why?
| | Hydrogen Bonding | 1 | 1999 | 1 | 0.010 |
Why?
| | Protein Structure, Secondary | 1 | 1999 | 1 | 0.010 |
Why?
| | Crystallography, X-Ray | 1 | 1999 | 4 | 0.010 |
Why?
| | Conserved Sequence | 1 | 1999 | 5 | 0.010 |
Why?
| | Models, Molecular | 1 | 1999 | 15 | 0.010 |
Why?
| | Cytochrome P-450 Enzyme Inhibitors | 1 | 1999 | 8 | 0.010 |
Why?
| | Phosphoadenosine Phosphosulfate | 1 | 1999 | 1 | 0.010 |
Why?
| | Nitrophenols | 1 | 1999 | 2 | 0.010 |
Why?
| | Analysis of Variance | 1 | 1998 | 25 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1998 | 8 | 0.010 |
Why?
| | Enzyme Stability | 1 | 1998 | 4 | 0.010 |
Why?
| | Germany | 1 | 1998 | 6 | 0.010 |
Why?
| | Haptens | 1 | 1996 | 3 | 0.010 |
Why?
| | Cytochrome P-450 CYP2E1 | 1 | 1996 | 4 | 0.010 |
Why?
| | Binding Sites, Antibody | 1 | 1996 | 4 | 0.010 |
Why?
| | Consensus Sequence | 1 | 1996 | 3 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1996 | 9 | 0.010 |
Why?
| | Gene Library | 1 | 1996 | 5 | 0.010 |
Why?
| | Blotting, Western | 1 | 1996 | 18 | 0.010 |
Why?
| | Peptide Fragments | 1 | 1996 | 12 | 0.010 |
Why?
| | Antibodies | 1 | 1996 | 16 | 0.010 |
Why?
| | Disease Susceptibility | 1 | 1995 | 11 | 0.010 |
Why?
| | Deoxyribonucleases, Type II Site-Specific | 1 | 1990 | 2 | 0.010 |
Why?
| | Urinary Bladder Neoplasms | 1 | 1990 | 3 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 1990 | 23 | 0.010 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|